Additionally, SGLT2 inhibitors have added benefits in patients with chronic kidney disease (CKD) by helping to prevent progression [17], which is a common co-morbidity of HF patients, as well as adverse effects from other guideline-directed heart failure therapies. This evidence concerns the gene SLC5A2 and hydrops fetalis.